Raphael Pharmaceutical names Uri Tadelis CFO after two departures
Raphael Pharmaceutical announced that Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026, and Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. The company appointed Uri Tadelis as Chief Financial Officer effective July 16, 2026. Neither resignation resulted from disagreement with the company regarding operations, policies, financial reporting, or governance.
Key facts
- Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026
- Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026
- Uri Tadelis appointed Chief Financial Officer effective July 16, 2026
Why it matters
The departures eliminate the former CFO and board chairman while establishing new financial leadership under Tadelis; the concurrent timing of these executive changes may signal a leadership transition.
Share
Derived from 8-K filed 2026-07-17. Not investment advice. View the source filing on SEC.gov →